Evidence map›Paper›PMID 27590105›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2017

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report.

Saro H Armenian, Wassim Chemaitilly, Marcus Chen, Eric J Chow, Christine N Duncan, Lee W Jones, Michael A Pulsipher, Alan T Remaley, Alicia Rovo, Nina Salooja and 1 more

Abstract readConsensus Development Conference, NIH
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Trial
  4. Childhood cancer and future cardiometabolic health.npj metabolic health and disease · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Saro H ArmenianDepartment of Population Sciences, City of Hope, Duarte, California. Electronic address: sarmenian@coh.org.
Wassim ChemaitillyPediatric Medicine Department, St. Jude Children's Research Hospital, Memphis, Tennessee.
Marcus ChenCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland.
Eric J ChowClinical Research and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Christine N DuncanPediatric Stem Cell Transplant Center, Dana Farber Cancer Institute, Boston, Massachusetts.
Lee W JonesDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Michael A PulsipherChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
Alan T RemaleyCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland.
Alicia RovoDepartment of Hematology, University Hospital of Bern, Bern, Switzerland.
Nina SaloojaDepartment of Medicine, Imperial College London, London, United Kingdom.
Minoo BattiwallaHematopoietic Transplantation Section, National Heart, Lung, and Blood Institute, Bethesda, Maryland.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Cardiovascular CT Clinical ResearchZIAHL006220 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CHEN, MARCUS · 2017 to 2025
$22.5M
Blood and Marrow Transplant Clinical Trials NetworkU10HL069254 · NHLBI · UNIVERSITY OF UTAH · PI PULSIPHER, MICHAEL A · 2011 to 2016
$839k
Determinants of late cardiovascular morbidity among survivors of hematopoietic ceK07CA151775 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHOW, ERIC JESSEN · 2011 to 2015
$755k
Development Of New Assays For Lipoprotein TestingZIACL010303 · CLC · CLINICAL CENTER · PI REMALEY, ALAN THOMAS · 2009 to 2017
$0k
NCI NIH HHS K07 CA151775NCI NIH HHS P30 CA008748NHLBI NIH HHS U10 HL069254
6 · The paper itself

Abstract

A number of studies have shown that autologous and allogeneic hematopoietic cell transplantation (HCT) contribute to an increased incidence of cardiovascular disease (CVD) and worsening of cardiovascular risk factors that could contribute to further CVD over time. These observations, combined with a notable increase in the number of survivors after HCT in recent years, highlight the need for studies aimed at modifying risk or preventing these outcomes by changing specific approaches and/or post-HCT interventions. To address these issues, the National Heart, Lung and Blood Institute and National Cancer Institute co-sponsored an international initiative on late effects after HCT. This report summarizes the major gaps in knowledge along with detailed recommendations regarding study priorities from the Cardiovascular Disease and Associated Risk Factors Committee, a multidisciplinary panel of international experts. The committee calls for specific studies aimed at understanding and preventing arterial disease and cardiac dysfunction (heart failure, valvular disease, and arrhythmias), as well as decreasing cardiovascular risk factors (hypertension, hyperglycemia, dyslipidemia, and sarcopenic obesity) after HCT.

Indexed as

AdultAllograftsCardiovascular DiseasesChildDyslipidemiasHematopoietic Stem Cell TransplantationHumansHyperglycemiaObesityResearchRetrospective StudiesRisk FactorsSarcopeniaSurvivorsTransplantation ConditioningCardiovascular diseaseCardiovascular risk factorsChronic diseaseHematopoietic cell transplantationLate effectsNational Institutes of Health consensusSurvivorship

Identifiers

PMID27590105
PMCPMC5526451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.